Effettuare il login Iscriviti gratis

OncoSec Medical Inc Le azioni fluttuano

Cos'è Le azioni fluttuano di OncoSec Medical Inc?

Le azioni fluttuano di OncoSec Medical Inc è 0.000 0.00%

Qual è la definizione di Le azioni fluttuano?

Le fluttuazione delle azioni è la parte di azioni di una società che sono nelle mani di investitori pubblici rispetto a azioni bloccate.

Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded

The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.

Le azioni fluttuano di aziende nel Health Care settore su NASDAQ rispetto a OncoSec Medical Inc

Cosa fa OncoSec Medical Inc?

oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar

Aziende con le azioni fluttuano simili a OncoSec Medical Inc